Structure via PubChem · Public domain (PubChem)
edivoxetine
Sign in to saveEdivoxetine (INN; code name LY-2216684) is a drug which acts as a selective norepinephrine reuptake inhibitor and was under development by Eli Lilly for attention-deficit disorder (ADD) and as an antidepressant treatment. It was in phase III clinical trials in 2012 for major depressive disorder, but failed to get approval.
Chemical data
- Formula
- C18H26FNO4
- Molecular weight
- 339.4 g/mol
- IUPAC name
- (1R)-2-(5-fluoro-2-methoxyphenyl)-1-[(2S)-morpholin-2-yl]-1-(oxan-4-yl)ethanol
- SMILES
- COC1=C(C=C(C=C1)F)C[C@]([C@@H]2CNCCO2)(C3CCOCC3)O
- InChIKey
- CPBHSHYQQLFAPW-ZWKOTPCHSA-N
- XLogP
- 1.3
- Polar surface area
- 60 Ų
- H-bond donors
- 2
- H-bond acceptors
- 6
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- attention deficit hyperactivity disorder, major depressive disorder
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 339.184587
Show 4 more facts
- chemical formula
- C₁₈H₂₆FNO₄
- canonical SMILES
- COC1=C(C=C(C=C1)F)CC(C2CCOCC2)(C3CNCCO3)O
- isomeric SMILES
- COC1=C(C=C(C=C1)F)C[C@]([C@@H]2CNCCO2)(C3CCOCC3)O
- Commons category
- Edivoxetine
Sources (2)
via Wikidata · CC0
~2 min read
Encyclopedic overview
4 sectionsContents
- Effectiveness
- Side effects
- See also
- References
Edivoxetine (INN; code name LY-2216684) is a drug which acts as a selective norepinephrine reuptake inhibitor and was under development by Eli Lilly for attention-deficit disorder (ADD) and as an antidepressant treatment. It was in phase III clinical trials in 2012 for major depressive disorder, but failed to get approval.
== Effectiveness == In a study published in 2010, edivoxetine succeeded to prove superiority over placebo, as measured by Hamilton Depression Rating Scale. However, effectiveness could be observed using the Self-Rated Quick Inventory of Depressive Symptomatology.
Excerpted from Wikipedia’s “edivoxetine” article, available under the CC BY-SA 4.0 licence.